ICU Medical (NASDAQ:ICUI) had its target price hoisted by stock analysts at Raymond James from $185.00 to $203.00 in a report released on Tuesday, The Fly reports. The firm currently has a “positive” rating on the medical instruments supplier’s stock. Raymond James’ target price suggests a potential upside of 16.37% from the stock’s current price.
Several other research analysts have also recently issued reports on ICUI. BidaskClub raised ICU Medical from a “sell” rating to a “hold” rating in a research note on Friday, October 25th. ValuEngine raised ICU Medical from a “sell” rating to a “hold” rating in a research report on Wednesday, October 2nd. TheStreet cut ICU Medical from a “b-” rating to a “c+” rating in a research report on Monday, August 12th. Finally, Zacks Investment Research cut ICU Medical from a “hold” rating to a “sell” rating in a research report on Wednesday, August 14th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the company’s stock. ICU Medical currently has an average rating of “Hold” and a consensus target price of $242.00.
ICU Medical stock traded down $0.28 during midday trading on Tuesday, reaching $174.44. 182,700 shares of the stock traded hands, compared to its average volume of 215,588. ICU Medical has a 12 month low of $148.89 and a 12 month high of $259.72. The stock has a market cap of $3.62 billion, a P/E ratio of 22.63 and a beta of 0.91. The stock’s fifty day moving average is $160.20 and its 200-day moving average is $200.93.
ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings data on Monday, November 11th. The medical instruments supplier reported $1.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.03. ICU Medical had a return on equity of 12.13% and a net margin of 5.66%. The company had revenue of $307.47 million for the quarter, compared to analysts’ expectations of $297.83 million. During the same quarter in the prior year, the firm earned $1.85 earnings per share. ICU Medical’s revenue was down 6.0% compared to the same quarter last year. As a group, research analysts predict that ICU Medical will post 7.1 EPS for the current fiscal year.
In other ICU Medical news, Director Robert S. Swinney sold 373 shares of the stock in a transaction on Monday, October 14th. The stock was sold at an average price of $153.49, for a total transaction of $57,251.77. Following the sale, the director now owns 18,845 shares of the company’s stock, valued at approximately $2,892,519.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Virginia Ruth Sanzone sold 3,000 shares of the stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $154.08, for a total value of $462,240.00. Following the sale, the vice president now directly owns 55 shares in the company, valued at approximately $8,474.40. The disclosure for this sale can be found here. 11.40% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Price T Rowe Associates Inc. MD boosted its position in shares of ICU Medical by 22.6% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 3,478,883 shares of the medical instruments supplier’s stock worth $876,365,000 after purchasing an additional 640,425 shares in the last quarter. Janus Henderson Group PLC boosted its position in shares of ICU Medical by 5.2% in the 2nd quarter. Janus Henderson Group PLC now owns 2,825,836 shares of the medical instruments supplier’s stock worth $711,856,000 after purchasing an additional 140,123 shares in the last quarter. BlackRock Inc. boosted its position in shares of ICU Medical by 4.9% in the 2nd quarter. BlackRock Inc. now owns 1,558,317 shares of the medical instruments supplier’s stock worth $392,555,000 after purchasing an additional 72,346 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of ICU Medical by 4.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 539,633 shares of the medical instruments supplier’s stock worth $133,867,000 after purchasing an additional 21,930 shares in the last quarter. Finally, Findlay Park Partners LLP boosted its position in shares of ICU Medical by 50.0% in the 3rd quarter. Findlay Park Partners LLP now owns 450,000 shares of the medical instruments supplier’s stock worth $71,820,000 after purchasing an additional 150,000 shares in the last quarter. 94.04% of the stock is currently owned by institutional investors and hedge funds.
About ICU Medical
ICU Medical, Inc develops, manufactures, and sells medical devices used in vascular therapy, critical care, and oncology applications worldwide. It offers infusion therapy products comprising a tube running from a bottle or plastic bag containing a solution to a catheter inserted in a patient's vein.
Featured Story: Hang Seng Index (HSI)
Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.